Lisata Therapeutics adds Jeffrey Farrow to board of directors

Lisata Therapeutics (LSTA) appointed Jeffrey Farrow to its board, effective October 13, 2026. Farrow, currently CFO of Tarsus Pharmaceuticals (TARS), will serve on the audit committee. Lisata is a clinical-stage pharmaceutical company developing treatments for severe hypertriglyceridemia and acromegaly.

Original reporting
Published Oct 14, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LSTA
Neutral
medium confidence
Mentioned
$LSTA
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LSTANeutralLow
01

Why it matters

The appointment is a standard governance update with limited immediate market impact.

02

Market read

A modest governance update for a micro‑cap biotech; unlikely to move the broader market.

03

What to watch

Farrow's prior roles at larger pharma may bring strategic partnerships opportunities.

Relevance 6/10Novelty 6/10Timing: effective Oct 13 2026

Background

Lisata Therapeutics is a clinical-stage biotech developing treatments for hypertriglyceridemia and acromegaly.

Company-level read

Ticker impact

$LSTANeutralMedium confidence
Context

Lisata Therapeutics announced the appointment of Jeffrey Farrow to its board of directors, a new executive change.

Expected impact

likely modest upward pressure as investors view the experienced appointment favorably

Evidence & confidence

Farrow brings CFO experience from multiple pharma firms; no immediate financial impact but may improve governance perception.

Market effects

Minor signal for biotech governance trends, no sector-wide impact.

U.S. biotech market unchanged.

Limited to Lisata investors.

Counterpoint

Board expansion could dilute focus and increase costs, potentially negative.

Key entities

  • Lisata Therapeutics

    Clinical-stage biotech (NASDAQ:LSTA).

  • Jeffrey Farrow

    New board member, former CFO of multiple pharma companies.

Related articles

$LSTAMedAI 8/10

Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial

Lisata Therapeutics' subsidiary Marea reported that its experimental antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial involved 235 adults with severe hypertriglyceridemia. MAR001 also reduced remnant cholesterol and showed a safety profile comparable to placebo. Marea has started Part B of the trial and is developing a longer-acting version, MAR005.

$LSTAMedAI 8/10

Marea Therapeutics doses first patient in MAR002 phase 2 trial

Lisata Therapeutics' (LSTA) subsidiary Marea Therapeutics dosed the first patient in a Phase 2 trial for MAR002, a treatment for acromegaly. The trial aims to enroll 72 participants, with primary endpoint measuring IGF-1 reduction after 10 weeks. MAR002 could offer less frequent dosing than current treatments. Lisata's valuation may be impacted by clinical milestones, according to InvestingPro.

$LSTALow

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.